Larvol Delta - GORTEC-202501-Phase-II-study-of-ficerafusp-alfa-in-combination-with-nivolumab-in-patients-with-platinumrefractory-head-and-neck-squamous-cell-carcinoma-who-progressed-within-6-months-of-multimodality-therapy-for-locally-advanced-disease

ficerafusp alfa (BCA101) - Bicara Therapeutics

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

https://euclinicaltrials.eu/ctis-public/view/2025-521437-88-00

Mar 5, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next